期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

做好靶向病理诊断 夯实肿瘤靶向治疗的基础 被引量：7

原文传递
导出
摘要 近30年随着肿瘤分子生物学研究的不断深入，特别是对癌基因和肿瘤抑制基因、生长因子和生长因子受体、调解肿瘤细胞生长和分化及凋亡的信号分子、肿瘤血管形成以及大量非随机出现在各种肿瘤的染色体易位等方面的研究成果地不断涌现，已为针对这些关键分子靶点开展肿瘤靶向治疗奠定了基础。
作者 郑杰
机构地区 北京大学医学部病理学系
出处 《中华病理学杂志》 CAS CSCD 北大核心 2007年第7期433-434,共2页 Chinese Journal of Pathology
关键词 肿瘤靶向治疗 病理诊断 生长因子受体 肿瘤分子生物学 肿瘤抑制基因 肿瘤细胞生长 肿瘤血管形成 染色体易位
分类号 R730.4 [医药卫生—肿瘤] R730.5 [医药卫生—临床医学]
  • 相关文献

参考文献9

  • 1Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma pmtuberans and giant-cell fibmblastoma. Nat Genet, 1997,15( 1 ) :95-98. 被引量：1
  • 2West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Nail Aead Sei U S A,2006,103(3) : 690-695. 被引量：1
  • 3Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 2006,42 ( 8 ) : 1093-1103. 被引量：1
  • 4Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 2006,24(29) :4764-4774. 被引量：1
  • 5Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell, 2002,2 : ( 2 ) 117-125. 被引量：1
  • 6Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med,2005,353( 19): 2012-2024. 被引量：1
  • 7<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：164
  • 8刘彤华.表皮生长因子受体家族与靶向性抗癌治疗[J].中华病理学杂志,2006,35(10):577-579. 被引量：21
  • 9步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量：24

二级参考文献20

  • 1Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114. 被引量：1
  • 2Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124. 被引量：1
  • 3Normanno N,De Luca A,Bianco C,et al.Epidermal growth factor receptor (EGFR) signaling in cancer.Gene,2006,366:2-16. 被引量：1
  • 4Normanno N,Bianco C,De Luca A,et al.Target-based agents against ErbB receptors and their ligands:a novel approach to cancer treatment.Endocr Relat Cancer,2003,10:1-21. 被引量：1
  • 5Lal P,Salazar PA,ladanyi M,et al.Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinoma without HER2/neu gene amplification.J Mol Diagn,2003,5:155-159. 被引量：1
  • 6Fornier M,Risio M,Van Poznak C,et al.HER2 testing and correlation with efficacy of trastuzumab therapy.Oncology,2002,16:1340-1348. 被引量：1
  • 7Saez A,Andreu FJ,Segui MA,et al.HER-2 gene amplification by chromogenic in situ hybridization (CISH) compared with fluorescence in situ hybridization (FISH) in breast cancer.A study of two hundred cases.Breast,2006,15:519-527. 被引量：1
  • 8Peiro G,Mayr D,Hillemanns P,et al.Analysis of HER2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization.Correlation with fluorescence in situ hybridization,HER-2/neu,p53 and Ki-67 protein expression,and outcome.Mod Pathol,2004,17:277-287. 被引量：1
  • 9Mass RD,Press MF,Anderson S,et al.Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.Clin Breast Cancer,2005,6:240-246. 被引量：1
  • 10Moroni M,Veronese S,Benvenuti S,et al.Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer:a cohort study.Lancet Oncol,2005,6:279-286. 被引量：1

共引文献197

同被引文献42

  • 1江泽飞,申戈.乳腺癌靶向药物治疗进展对临床病理学的需求[J].中华病理学杂志,2007,36(7):435-437. 被引量：5
  • 2沈琳.胃肠道肿瘤化疗及靶向药物治疗对病理学发展的需求[J].中华病理学杂志,2007,36(7):438-439. 被引量：11
  • 3Suzanne Kosmider,Lara Lipton.Adjuvant therapies for colorectal cancer[J].World Journal of Gastroenterology,2007,13(28):3799-3805. 被引量：7
  • 4Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1. 0. IARC Cancer Base No. 5. Lynn: 1ARC 2001. 被引量：1
  • 5Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxie T-lymphoeytes in cancer patients by autologous tumor RNA- transfected dendritic cells [ J ]. Ann Surg, 2002, 235 (4) : 540-549. 被引量：1
  • 6Nakano M, Aoki K, Matsumoto N, et al. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA [J]. MolTher, 2001, 3(4): 491-499. 被引量：1
  • 7Shi W, Teschendorf C, Muzyczka N, et al. Adeno-associated virusmediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo [J]. Cancer Gene Ther, 2002, 9(6): 513-521. 被引量：1
  • 8Tabernero J. The role of VEGF and EGFR inhibition:implications for combining anti-VEGF and anti-EGFR agents [ J ]. Mol Cancer Res, 2007, 5 ( 3 ) : 203-220. 被引量：1
  • 9Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of eolorectal cancer patients [ J ]. PLoS One, 2011, 6(1): e15980. 被引量：1
  • 10Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase Ⅲ study in patients with previously treated metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CON-FIRM2) (abst) [J]. Proc Am Soc Clin Oncol, 2006, 24:18s. 被引量：1

引证文献7

二级引证文献24

中华病理学杂志
2007年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部